Abstract:Platelet chemokine receptors play a crucial role in platelet signalling and function. Unlike most other chemokine receptors, the atypical chemokine receptor ACKR3 is a platelet inhibitory receptor. Here, we demonstrate that ACKR3 agonism leads to heterodimerization with chemokine receptor CXCR4 in platelets, thereby inhibiting CXCR4 platelet activation signalling. CXCL12‐dependent platelet aggregation, thrombus formation and signalling via CXCR4 is significantly diminished by ACKR3 agonism and therefore associated with CXCR4/ACKR3 heterodimerization. Background Platelet receptors ACKR3 and CXCR4 play a crucial role in a variety of cardiovascular diseases. Like most chemokine receptors, CXCR4 is a G protein coupled receptor that induces platelet activation. In contrast, the atypical chemokine receptor 3 (ACKR3) lacks the ability to activate heterotrimeric G proteins and its activation leads to platelet inhibition and attenuates thrombus formation. In nucleated cells, heterodimerization of ACKR3 with CXCR4 regulates CXCL12‐dependent signalling. The aim of our study was to investigate the formation of ACKR3/CXCR4 heterodimers in platelets and the subsequent consequences for platelet function. Methods and Results Using a proximity ligation assay (PLA, Duolink®) to screen for CXCR4/ACKR3 heterodimerization inducing compounds, we found that ACKR3 agonism but not conventional platelet agonists or endogen ligands lead to heterodimer formation. To further characterize the formation of ACKR3/CXCR4 heterodimers, we studied the CXCL12‐dependent platelet activation via CXCR4. Both, CXCL12‐dependent platelet aggregation and collagen‐dependent ex vivo thrombus formation were significantly downregulated by ACKR3 agonism. Moreover, platelet intracellular calcium and Akt signalling were increased by CXCL12 and again suppressed by ACKR3‐specific agonists. Previously, CXCL12 was shown to decrease platelet cAMP levels via CXCR4. Treatment with a specific ACKR3 agonist counteracted this CXCL12/CXCR4‐dependent cAMP decrease. Conclusion Our results reveal that the formation of platelet ACKR3/CXCR4 heterodimers is dependent on ACKR3 rather than CXCR4. Furthermore, ACKR3 agonism induced heterodimerization is associated with mitigating CXCL12/CXCR4‐dependent platelet activation possibly by modulating CXCR4‐dependent G protein signalling. Our results indicate possible ACKR3 agonist functions and reinforce the potential therapeutic applications of ACKR3 agonists.

Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes

Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias

Conformational dynamics underlying atypical chemokine receptor 3 activation

The Role of SDF‐1 in Signaling Differences Between CXCR4 and Atypical ACKR3 Chemokine Receptors

Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies

Identification of critical residues at the C-terminal tip of ACKR4 regulating chemokine internalization and βarrestin involvement

Structural insights into CXCR4 modulation and oligomerization

ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function

Structural insights into the activation and inhibition of CXC chemokine receptor 3

CXCR4/ACKR3 Phosphorylation and Recruitment of Interacting Proteins: Key Mechanisms Regulating Their Functional Status

Biophysical characterization of the CXC chemokine receptor 2 ligands

C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways

Atypical chemokine receptors in the immune system

Interaction and dynamics of chemokine receptor CXCR4 binding with CXCL12 and hBD-3

β-Arrestin1 and β-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4

A high-resolution analysis of arrestin2 interactions responsible for CCR5 endocytosis

CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways

Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3

Structural insights into the activation of chemokine receptor CXCR2